

**Pfizer** 40 mg/mL & 76 mg/1.9 mL single-dose vials SC injection — step-up → weekly → q2wk **Reviewed:** May 2, 2026 **ASP:** Q2 2026

<b>HCPCS</b> <b>J1323</b> 1 mg = 1 unit	<b>FULL DOSE</b> <b>76 units</b> 76 mg SC weekly → q2wk	<b>MODIFIER</b> <b>JZ/JW</b> JZ on 76 mg; JW on step-up waste	<b>ADMIN CPT</b> <b>96401</b> Chemo SC (or 96372 per payer)	<b>MEDICARE ASP+6%</b> <b>\$186.791</b> /mg · \$14,196.12/76 mg
---	---	---	---	---

**CODES & NDC**

HCPCS	J1323 — "Inj, elranatamab-bcmm, 1 mg"
NDC (40 MG)	0069-1019-01 — 40 mg/mL single-dose vial (step-up)
NDC (76 MG)	0069-1018-01 — 76 mg/1.9 mL single-dose vial (full dose)
BLA	761345 — FDA accelerated approval Aug 14, 2023 (MagnetisMM-3)
BENEFIT	Medical (Part B / commercial medical)

**ICD-10 — MULTIPLE MYELOMA**

CODE	FOR
C90.00	MM not in remission
C90.01	MM in remission (rare for Elrexio)
C90.02	<b>MM in relapse</b> — most common

**Indication:** R/R MM after ≥4 prior lines incl. PI + IMiD + anti-CD38 mAb. Submit complete prior-therapy history with PA.

**STEP-UP DOSING SCHEDULE**

DAY	DOSE	VIAL	HOSPITALIZE
Day 1	12 mg SC	40 mg vial (waste 28 mg)	48 hr
Day 4	32 mg SC	40 mg vial (waste 8 mg)	48 hr
Day 8	76 mg SC (first full)	76 mg vial (no waste)	48 hr
Wk 2–24	76 mg SC weekly	76 mg vial	Outpatient
Wk 25+	76 mg SC q2wk	76 mg vial	Outpatient

Step-up doses spaced 2–4 days. Restart from Day 1 if >14 days elapse between step-up doses. Premedicate (dex 20 mg + diphenhydramine + APAP) ~1 hr before step-up doses + first full dose.

**BCMA BISPECIFIC PEERS**

	ELREXFIO	TECVAYLI	TALVEY
HCPCS	J1323	J9286	J3055
Target	BCMA	BCMA	GPRC5D
Step-up	Fixed	Weight	Weight
Maint	<b>q2wk by label</b>	Weekly (opt q2wk)	Weekly OR q2wk
CRS	~58%	~72%	~76%
ICANS	~3.4%	~6%	~10%

**ELREXFIO REMS — REQUIRED**

**Pfizer-managed REMS.** Site, prescriber, pharmacy, AND patient must be certified before first dose. Wallet card required.

- **Phone:** 1-844-353-7394 (ELREXFIO REMS Coordinating Center)
- **Web:** elrexfiorems.com
- Pfizer Oncology Together: 1-877-744-5675 (clinical/access)
- Tocilizumab ( J3262 ) on-site: ≥2 doses per patient per REMS

**Common error:** using TECVAYLI REMS or TALVEY REMS cert for Elrexio. Each bispecific requires separate REMS certification.

**PAYER REQUIREMENTS (MAY 2026)**

PAYER	PA	STEP / PREFERENCE
UnitedHealthcare	Yes	≥4L docs (PI+IMiD+anti-CD38) + REMS
Aetna	Yes	≥4L docs + REMS verification + SOC steering
Cigna	Yes	NCCN Cat 1/2A + full prior-therapy history
Medicare (MAC)	No	FDA-label or NCCN-listed; REMS-certified site

**Sequencing:** some payers require Tecvayli failure docs before Elrexio (or vice versa). NCCN lists both Cat 2A without preferred order.

**MEDICARE REIMBURSEMENT (Q2 2026)**

FIELD	VALUE
ASP + 6%	<b>\$186.791 / mg</b> (eff. 4/1 – 6/30/2026)
12 mg step-up Day 1	\$2,241.49
32 mg step-up Day 4	\$5,977.31
76 mg full dose	<b>\$14,196.12</b>
Year-1 (q2wk transition)	~\$533,475 (~2,856 units)
Year-1 (weekly forever)	~\$724,000 (~3,876 units)

## ADMINISTRATION & MODIFIERS

CODE	WHEN
96401	Chemo SC, non-hormonal anti-neoplastic (primary)
96372	Therapeutic SC injection (some payers)
JZ	Required on every 76 mg dose (no waste)
JW	Required on step-up doses: 28 units (Day 1) / 8 units (Day 4)

**Inpatient bundling:** J1323 admin during inpatient observation stay is bundled into DRG (837/846). Use observation status (POS 22) if you want J1323 separately billable.

**Q2wk transition is the differentiator:** response by cycle 6 ( $\geq$ PR per IMWG) unlocks 76 mg q2wk maintenance per FDA label. Saves ~12 doses/year (~\$170K drug cost) AND ~12 chair-time visits versus weekly-forever bispecifics. Plan PA documentation around the cycle-6 response assessment.

## PATIENT ASSISTANCE — PFIZER ONCOLOGY TOGETHER

- **Phone:** 1-877-744-5675 (Pfizer Oncology Together)
- **Commercial copay:** Elrexfio Co-Pay Savings Card (excludes Medicare/Medicaid)
- **PAP:** free product through Pfizer Patient Assistance Foundation (uninsured/underinsured)
- **Medicare foundations:** PAN MM Fund, HealthWell, CancerCare, LLS Co-Pay
- **REMS:** 1-844-353-7394
- **Web:** pfizeroncologytogether.com

**BOXED WARNING — CRS & ICANS:** Cytokine release syndrome (life-threatening, ~58% any-grade) and neurologic toxicity including ICANS (life-threatening, ~3.4%). Initiate only at REMS-certified sites with tocilizumab on-hand and ICU access. 48-hr inpatient observation required after step-up doses 1, 2, AND first full 76 mg dose Day 8.